MCM
ATRA icon

Moore Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Moore Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$364K – 377
2020
Q2 		$364K Buy
+1,000
New +$253K 0.01% 232

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Moore Capital Management's ATRA Position: Q3 2020 in Review

Moore Capital Management sold out of Atara Biotherapeutics (ATRA) in Q3 2020, closing a stake of 1,000 shares — an estimated $364K sold.

Moore Capital Management first reported a position in ATRA in Q2 2020 and held it in 1 quarter. The position peaked at $364K in Q2 2020. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2020.

  • Moore Capital Management reported no remaining Atara Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Moore Capital Management sold 1,000 Atara Biotherapeutics shares in Q3 2020, an estimated $364K.
  • Moore Capital Management first reported a position in Atara Biotherapeutics in Q2 2020 and held it in 1 quarter.
  • Moore Capital Management's Atara Biotherapeutics position peaked at $364K in Q2 2020.
  • 140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2020.

Based on Moore Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.